· Periodic Report
Q3 operating loss of KRW 19.9 billion on revenue of KRW 8.8 billion
ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.
298380 · KOSDAQ · Based on DART filings
3 total · 20 per page
· Periodic Report
ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.
· Report on Large Shareholdings
Largest shareholder Lee Sang-hoon's stake is unchanged at 24.53%, with 3,982,035 shares under contracts, the nearest expiry being Dec 31, 2026.
· Report on Large Shareholdings
The stake of largest shareholder LEE SANGHOON's group in ABL Bio Inc. fell from 24.54% to 24.53% after related parties disposed of 3,600 shares at KRW 45,400-45,414.
Get app alerts for new disclosures from ABL Bio Inc..